Berdazimer sodium - SB 207 - Ligand Pharmaceuticals
Alternative Names: SB-207Latest Information Update: 25 Jun 2024
At a glance
- Originator University of North Carolina at Chapel Hill
- Developer Ligand Pharmaceuticals; Novan Inc
- Class Anti-inflammatories; Antiacnes; Antiandrogens; Antibacterials; Antifibrotics; Antifungals; Antihypertensives; Antipsoriatics; Antivirals; Esters; Macromolecular substances; Nitrogen oxides; Nitroso compounds; Non-opioid analgesics; Propylamines; Silicates; Silicon compounds; Skin disorder therapies; Vasodilators
- Mechanism of Action Androgen receptor antagonists; Angiogenesis inducing agents; Cell death stimulants; Guanylate cyclase stimulants; Interleukin 13 inhibitors; Interleukin 4 inhibitors; Nitric oxide donors; NLRP3 protein inhibitors; Reactive oxygen species modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Genital warts
- Discontinued Viral infections
Most Recent Events
- 27 Sep 2023 Ligand Pharmaceuticals acquires all the rights of all the assets related to the NITRICIL technology platform from Novan
- 05 Apr 2023 Discontinued - Preclinical for Viral infections in USA (Topical) (Novan Inc Pipeline, April 2023)
- 31 Dec 2020 Phase-II clinical trials in Genital warts in USA (Topical) before December 2020